Filing Details
GT Biopharma, Inc. (NASDAQ:GTBP) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 14, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:GTBP
GT Biopharma, Inc. (GTBP) Files Quarterly Report for Q0
GT Biopharma, Inc. (NASDAQ:GTBP) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 14, 2026.
At publication ·
What changed
GT Biopharma, Inc. (NASDAQ:GTBP) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- GT Biopharma, Inc. filed its quarterly report (Form 10-Q) with the SEC on August 14, 2026, providing unaudited financial statements and management commentary for Q0.
- The company's stock trades at $0.30 per share with a market capitalization of $6.8 million.
- The 10-Q filing contains timely information about emerging trends, updated risk factors, and changes in business conditions, though it is less detailed than the annual 10-K report.
Market Context
GT Biopharma, Inc.'s stock currently trades at $0.30 with a market capitalization of $6.8M.
The 10-Q provides GT Biopharma, Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for GT Biopharma, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View GTBP Stock Page
Frequently Asked Questions
Where can I read GTBP's SEC filings?
Browse all filings on our GTBP SEC filings page.
What types of SEC filings does GT Biopharma, Inc. file?
Public companies like GT Biopharma, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.